188 related articles for article (PubMed ID: 25088707)
1. Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth.
Obinata D; Ito A; Fujiwara K; Takayama K; Ashikari D; Murata Y; Yamaguchi K; Urano T; Fujimura T; Fukuda N; Soma M; Watanabe T; Nagase H; Inoue S; Takahashi S
Cancer Sci; 2014 Oct; 105(10):1272-8. PubMed ID: 25088707
[TBL] [Abstract][Full Text] [Related]
2. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
3. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
6. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
7. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
10. Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide.
Hargrove AE; Martinez TF; Hare AA; Kurmis AA; Phillips JW; Sud S; Pienta KJ; Dervan PB
PLoS One; 2015; 10(11):e0143161. PubMed ID: 26571387
[TBL] [Abstract][Full Text] [Related]
11. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
Zammarchi F; Boutsalis G; Cartegni L
PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
Barry M; Perner S; Demichelis F; Rubin MA
Urology; 2007 Oct; 70(4):630-3. PubMed ID: 17991527
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
Mani RS; Iyer MK; Cao Q; Brenner JC; Wang L; Ghosh A; Cao X; Lonigro RJ; Tomlins SA; Varambally S; Chinnaiyan AM
Cancer Res; 2011 Aug; 71(16):5387-92. PubMed ID: 21676887
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
[TBL] [Abstract][Full Text] [Related]
18. RNA binding properties of novel gene silencing pyrrole-imidazole polyamides.
Iguchi A; Fukuda N; Takahashi T; Watanabe T; Matsuda H; Nagase H; Bando T; Sugiyama H; Shimizu K
Biol Pharm Bull; 2013; 36(7):1152-8. PubMed ID: 23628892
[TBL] [Abstract][Full Text] [Related]
19. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
Gopalan A; Leversha MA; Satagopan JM; Zhou Q; Al-Ahmadie HA; Fine SW; Eastham JA; Scardino PT; Scher HI; Tickoo SK; Reuter VE; Gerald WL
Cancer Res; 2009 Feb; 69(4):1400-6. PubMed ID: 19190343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
